Clinical Utility of Capsule Endoscopy and Double-Balloon Enteroscopy in the Management of Obscure Gastrointestinal Bleeding.

BACKGROUND: Obscure gastrointestinal bleeding (OGIB) is a common but embarrassing problem for gastroenterologists. Most bleeding lesions associated with OGIB are present in the small intestine and sometimes cannot be identified due to the difficulty associated with physical accessibility. Capsule endoscopy (CE) and double-balloon enteroscopy (DBE) have enabled in the process of diagnosing and have evolved to become approaches to treating OGIB. SUMMARY: CE is a minimally invasive procedure and has a high diagnostic yield in patients with OGIB. DBE offers additional advantage of biopsy collection for pathological diagnosis and therapeutic intervention, but it should be noted that it sometimes causes severe adverse events such as acute pancreatitis, intestinal bleeding, and intestinal perforation. CE should be performed early in the workup course of OGIB. Positive CE findings enhance the diagnostic yield of subsequent DBE, and the effective therapeutic intervention improves the clinical outcomes of OGIB patients. On the contrary, there are no clear guidelines for further investigation of patients with negative CE findings at the present. Although patients in stable general condition may only require follow-up, repeated CE is useful to detect positive findings in patients with evidence of sustained bleeding and progressing anemia. We have revealed that repeated CE has higher positive finding rate than DBE in OGIB patients with negative CE findings in a preliminary study. Key Messages: CE and DBE have complementary roles in the management of OGIB, and the precise timing and proper sequence may be important for the approach to treating OGIB.

Regional brain disorders of serotonin neurotransmission are associated with functional dyspepsia.

AIMS: To elucidate the role of cerebral serotonin neurotransmission in visceral perception in functional dyspepsia (FD), we observationally examined the regional expression level of the serotonin transporter (SERT) and its correlation with clinical symptoms. MAIN METHODS: FD patients (Rome III criteria; N=9, age range: 36-76years) and healthy controls (N=8, age range: 25-61years) participated in this study. Positron emission tomography scanning with [(11)C]N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine ([(11)C]DASB), which binds specifically to SERT, was used to quantify the binding potential (BPND) of [(11)C]DASB in the midbrain, thalamus, caudate, putamen, amygdala, and hippocampus with reference to co-registered magnetic resonance images. Clinical symptoms were assessed using the Gastrointestinal Symptoms Rating Scale (GSRS). Self-Rating Depression Scale (SDS), and State-Trait Anxiety Inventory (STAI). KEY FINDINGS: BPND of the midbrain (P=0.041) and thalamus (P=0.031) was higher in FD patients than in controls. The BPND values in the midbrain correlated with total GSRS (r=0.663, P=0.004) and abdominal pain (r=0.419, P=0.047) scores. Its values in the thalamus correlated with total GSRS (r=0.423, P=0.044), abdominal pain (r=0.502, P=0.022), and indigestion (r=0.476, P=0.028) scores. Its value in the hippocampus correlated with abdominal pain and state-STAI scores (r=0.528, P=0.017; r=0.428, P=0.043). SIGNIFICANCE: Up-regulation of the SERT level in the midbrain and thalamus may underlie the pathogenesis of FD such as abdominal and psychological symptoms via a brain-gut interaction.

Usefulness of magnetic resonance imaging for detection of asymptomatic osteonecrosis of the femoral head in patients with inflammatory bowel disease on long-term corticosteroid treatment.

OBJECTIVE: Osteonecrosis of the femoral head is one of the serious side effects of corticosteroid therapy. Early-stage osteonecrosis can now be diagnosed by magnetic resonance imaging even in asymptomatic patients. The aim of this study was to assess the usefulness of magnetic resonance imaging in diagnosing early osteonecrotic change and to determine whether corticosteroid administration is related to the development of osteonecrosis. MATERIAL AND METHODS: We examined the relationship between osteonecrosis and corticosteroid administration, including maximum dosage, cumulative lifetime dose, duration, and bone mineral density in 20 patients with refractory inflammatory bowel disease requiring long-term corticosteroid treatment. Osteonecrosis of the femoral head was assessed by magnetic resonance imaging, and bone mineral density by osteodensitometry of the lumbar spine. RESULTS: Osteonecrosis was diagnosed in 5 male patients including 4 in the asymptomatic stage. Cumulative lifetime dose of corticosteroid, duration of corticosteroid treatment, and steroid.pulse therapy did not appear to be associated with the development of osteonecrosis. Maximum daily corticosteroid dose was significantly higher for patients with osteonecrosis than for those without it. Administration of 50 mg prednisolone for at least 14 days was a risk factor for osteonecrosis. Development of osteoporosis appeared not to be related to osteonecrosis. CONCLUSIONS: We conclude that high-dose corticosteroid treatment increases the risk of osteonecrosis, which may be due to different mechanisms from those responsible for osteoporosis. Magnetic resonance imaging is essential for diagnosis of asymptomatic osteonecrosis in patients receiving high-dose corticosteroids.